1. Manipulation of CD98 Resolves Type 1 Diabetes in Nonobese Diabetic Mice.
- Author
-
Lian, Gaojian, Arimochi, Hideki, Kitamura, Akiko, Nishida, Jun, Shigen Li, Kishihara, Kenji, Maekawa, Yoichi, and Yasutomo, Koji
- Subjects
- *
CD98 antigen , *DIABETES , *LABORATORY mice , *CD4 antigen , *CD8 antigen , *AUTOANTIGENS , *DISEASE progression , *AUTOIMMUNE diseases - Abstract
The interplay of CD4+ and CD8+ T cells targeting autoantigens is responsible for the progression of a number of autoimmune diseases, including type 1 diabetes mellitus (T1D). Understanding the molecular mechanisms that regulate T cell activation is crucial for designing effective therapies for autoimmune diseases. We probed a panel of Abs with T cell-modulating activity and identified a mAb specific for the H chain of CD98 (CD98hc) that was able to suppress T cell proliferation. The anti-CD98hc mAb also inhibited Ag-specific proliferation and the acquisition of effector function by CD4+ and CD8+ T cells in vitro and in vivo. Injection of the anti-CD98hc mAb completely prevented the onset of cyclophosphamide-induced diabetes in NOD mice. Treatment of diabetic NOD mice with anti-CD98hc reversed the diabetic state to normal levels, coincident with decreased proliferation of CD4+ T cells. Furthermore, treatment of diabetic NOD mice with CD98hc small interfering RNA resolved T1D. These data indicate that strategies targeting CD98hc might have clinical application for treating T1D and other T cell-mediated autoimmune diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF